Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Neisseria meningitidis is an important cause of bacterial meningitis and septicaemia with most disease caused by meningococci bearing serogroups A, B, C, Y and W-135 polysaccharides. Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal vaccine, containing the polysaccharides from 4 of the serogroups A, C, Y and W-135 meningococci conjugated to a protein carrier was licensed in the US in 2005. This vaccine and others in development offer the potential to broaden population protection against meningococcal disease.

Original publication




Journal article



Publication Date



27 Suppl 2


B30 - B41


Humans, Meningitis, Meningococcal, Meningococcal Vaccines, Neisseria meningitidis, Serogroup A, Neisseria meningitidis, Serogroup B, Neisseria meningitidis, Serogroup C, Neisseria meningitidis, Serogroup W-135, Sepsis, United States, Vaccines, Conjugate